News

Resident News

11/25/2019

Caelus Health and Nestlé Health Science sign exclusive global development & option agreement on Caelus’ microbiome-based food supplements

By JLABS

Read full story

Resident News

11/07/2019

Syndesi Therapeutics announces successful completion of first-in-human Phase I study of novel SV2A modulator

By JLABS

Read full story

Other news

05/13/2019

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.

By JLABS

Read full story

Other news

03/21/2019

Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment

By JLABS

Read full story

Other news

02/25/2019

Calypso Biotech BV secures 20 Million EUR in Series A Financing to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases

By JLABS

Read full story

Other news

11/05/2018

Genome Biologics wins prestigious Horizon 2020 EU Phase 2 grant award

By JLABS

Read full story

In the media

07/02/2018

Johnson & Johnson Opens JLABS @ NYC

By Global Cosmetic Industry

Read full story

Other news

04/29/2018

Riding the Start-Up Roller Coaster: What It's Really Like to Be a Healthcare Entrepreneur

By Leena Rao

Read full story

Other news

03/15/2018

IDEAYA Biosciences raised a $94M crossover Series B financing to develop next generation biomarker-enabled synthetic lethality therapies.

By Ideaya Biosciences

Read full story

Other news

02/12/2018

Sirenas LLC. annouced today they have entered a muti-target research collaboration agreement with Bristol-Myers Squibb to deploy a drug discovery platform against undisclosed challenging therapeutic targets

By JLABS

Read full story

Other news

02/12/2018

Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials

By JLABS

Read full story

Other news

02/08/2018

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

By JLABS

Read full story

Other news

02/08/2018

Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies

By JLABS

Read full story

Other news

02/07/2018

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, announced they are entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates

By JLABS

Read full story

Other news

02/01/2018

JLABS TMC Company finds Growth in Shrinking Cells

By JLABS

Read full story

A look back at BIO-Europe 2019

Caelus Health and Nestlé Health Science sign exclusive global development & option agreement on Caelus’ microbiome-based food supplements

Syndesi Therapeutics announces successful completion of first-in-human Phase I study of novel SV2A modulator

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.

Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment

Calypso Biotech BV secures 20 Million EUR in Series A Financing to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases

Genome Biologics wins prestigious Horizon 2020 EU Phase 2 grant award

Johnson & Johnson Opens JLABS @ NYC

Riding the Start-Up Roller Coaster: What It's Really Like to Be a Healthcare Entrepreneur

IDEAYA Biosciences raised a $94M crossover Series B financing to develop next generation biomarker-enabled synthetic lethality therapies.

Sirenas LLC. annouced today they have entered a muti-target research collaboration agreement with Bristol-Myers Squibb to deploy a drug discovery platform against undisclosed challenging therapeutic targets

Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, announced they are entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates

JLABS TMC Company finds Growth in Shrinking Cells

Video: Championing Science: If we use AI to detect Alzheimer’s

News

Main tabs

Caelus Health and Nestlé Health Science sign exclusive global development & option agreement on Caelus’ microbiome-based food supplements

Syndesi Therapeutics announces successful completion of first-in-human Phase I study of novel SV2A modulator

Syndesi Therapeutics announces initiation of Phase I study of novel SV2A modulator, SDI‐118, in development for the treatment of cognitive impairment.

Syndesi Therapeutics Awarded Non-dilutive Funding of up to €3.2M for Development of its Lead Program, SDI-118, Aimed at Treating Cognitive Impairment

Calypso Biotech BV secures 20 Million EUR in Series A Financing to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases

Genome Biologics wins prestigious Horizon 2020 EU Phase 2 grant award

Johnson & Johnson Opens JLABS @ NYC

Riding the Start-Up Roller Coaster: What It's Really Like to Be a Healthcare Entrepreneur

IDEAYA Biosciences raised a $94M crossover Series B financing to develop next generation biomarker-enabled synthetic lethality therapies.

Sirenas LLC. annouced today they have entered a muti-target research collaboration agreement with Bristol-Myers Squibb to deploy a drug discovery platform against undisclosed challenging therapeutic targets

Nanovista Inc. closes $2.3 million seed round to advance its multimodal visualization agent towards clinical trials

Symic Bio Completes the MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Knee Osteoarthritis

Imago BioSciences Receives FDA Approval of IND Application for the Treatment of Myeloid Malignancies

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, announced they are entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates

JLABS TMC Company finds Growth in Shrinking Cells

A look back at BIO-Europe 2019

Video: Championing Science: If we use AI to detect Alzheimer’s